A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI5884 in Healthy Volunteers
Latest Information Update: 05 Nov 2021
At a glance
- Drugs REG-101 (Primary)
- Indications Cardiovascular disorders; Coronary artery disease
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors MedImmune
- 21 Aug 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2018 Planned End Date changed from 3 Aug 2018 to 27 Jul 2018.
- 08 May 2018 Planned primary completion date changed from 3 Aug 2018 to 27 Jul 2018.